Sec Form 4 Filing - Waldman Louis S. @ IRADIMED CORP - 2020-07-24

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Waldman Louis S. 2. Issuer Name and Ticker or Trading Symbol IRADIMED CORP [ IRMD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner _____ Officer (give title below) X __ Other (specify below) Former Controller (Last) (First) (Middle) C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR. 3. Date of Earliest Transaction (MM/DD/YY) 07/24/2020 (Street) WINTER SPRINGS, FL32708 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 07/24/2020 M( 1 ) 5,155 A $ 0 40,155 D Common Stock 07/24/2020 F 1,254 ( 2 ) D $ 23.47 38,901 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Units ( 3 ) 07/24/2020 M( 1 ) 750 ( 4 ) ( 4 ) Common Stock 750 $ 0 0 D Restricted Stock Units ( 3 ) 07/24/2020 M( 1 ) 1,476 ( 4 ) ( 4 ) Common Stock 1,476 $ 0 0 D Restricted Stock Units ( 3 ) 07/24/2020 M( 1 ) 1,181 ( 4 ) ( 4 ) Common Stock 1,181 $ 0 0 D Restricted Stock Units ( 3 ) 07/24/2020 M( 1 ) 1,748 ( 4 ) ( 4 ) Common Stock 1,748 $ 0 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Waldman Louis S. C/O IRADIMED CORPORATION 1025 WILLA SPRINGS DR. WINTER SPRINGS, FL32708 Former Controller Signatures /s/ Louis S. Waldman 07/27/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )As previously disclosed, the reporting person received restricted stock units under the Issuer's 2014 Equity Incentive Plan on December 14, 2016, December 4, 2017, December 7, 2018, and December 7, 2019. Pursuant to the reporting person's separation agreement with the Issuer (the "Separation Agreement"), upon his separation from the Issuer on July 24, 2020 (the "Retirement Date"), all of his unvested restricted stock units, amounting to 5,155 shares of common stock, accelerated and vested as of the Retirement Date as follows: (i) 750 unvested restricted stock units accelerated and vested from the December 14, 2016 grant; (ii) 1,476 unvested restricted stock units accelerated and vested from the December 4, 2017 grant; (iii) 1,181 unvested restricted stock units accelerated and vested from the December 7, 2018 grant; and (iv) 1,748 unvested restricted stock units accelerated and vested from the December 7, 2019 grant (collectively, the "RSUs"). ( 2 )Shares surrendered to the Issuer for payment of tax liability incident to the accelerated vesting of a total of 5,155 restricted stock units. ( 3 )Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. ( 4 )All of the unvested RSUs were accelerated on the Retirement Date pursuant to the terms of the Separation Agreement.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.